Business Description
Mangoceuticals Inc
NAICS : 923120
SIC : 7372
ISIN : US56270V2051
Description
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.6 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.68 | |||||
Beneish M-Score | -6.99 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 71 | |||||
3-Year EBITDA Growth Rate | 1.4 | |||||
3-Year EPS without NRI Growth Rate | -1.3 | |||||
3-Year FCF Growth Rate | 24.7 | |||||
3-Year Book Growth Rate | 16.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 77.42 | |||||
9-Day RSI | 73 | |||||
14-Day RSI | 68.03 | |||||
3-1 Month Momentum % | 4.53 | |||||
6-1 Month Momentum % | -12.53 | |||||
12-1 Month Momentum % | -77.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.29 | |||||
Quick Ratio | 0.29 | |||||
Cash Ratio | 0.24 | |||||
Days Payable | 1267.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -149.7 | |||||
Shareholder Yield % | -42.79 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.42 | |||||
Operating Margin % | -4209.42 | |||||
Net Margin % | -4639.37 | |||||
EBITDA Margin % | -4157.73 | |||||
FCF Margin % | -1180.19 | |||||
OCF Margin % | -1180.19 | |||||
ROE % | -114.46 | |||||
ROA % | -107.1 | |||||
ROIC % | -98.83 | |||||
3-Year ROIIC % | -119.87 | |||||
ROC (Joel Greenblatt) % | -13534.53 | |||||
ROCE % | -111.81 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 15.11 | |||||
PB Ratio | 0.67 | |||||
EV-to-EBIT | -0.49 | |||||
EV-to-EBITDA | -0.53 | |||||
EV-to-Revenue | 22.21 | |||||
EV-to-FCF | -1.88 | |||||
Price-to-GF-Value | 1.65 | |||||
Earnings Yield (Greenblatt) % | -204.08 | |||||
FCF Yield % | -53.84 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MGRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mangoceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.414 | ||
| EPS (TTM) ($) | -1.49 | ||
| Beta | 1.9557 | ||
| 3-Year Sharpe Ratio | -0.66 | ||
| 3-Year Sortino Ratio | -0.82 | ||
| Volatility % | 112.56 | ||
| 14-Day RSI | 68.03 | ||
| 14-Day ATR ($) | 0.053824 | ||
| 20-Day SMA ($) | 0.434775 | ||
| 12-1 Month Momentum % | -77.99 | ||
| 52-Week Range ($) | 0.162 - 2.75 | ||
| Shares Outstanding (Mil) | 17.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mangoceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mangoceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 107 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 16 days | ||
| First quarter earnings results for 2026 | 2026-05-19 | 0.41 (-3.80%) | ||
| Annual report for 2025 | 2026-04-01 | 0.36 (-11.89%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.19 (-45.16%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 1.70 (+2.41%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 1.57 (-3.40%) | ||
| Annual report for 2024 | 2025-03-20 | 4.27 (+19.44%) | ||
| Third quarter earnings results for 2024 | 2024-11-14 | 2.43 (+0.00%) | ||
| 0.0666667:1 Stock Split | 2024-10-16 | 2.65 (-2.43%) |
Show
Entries
Mangoceuticals Inc Frequently Asked Questions
What is Mangoceuticals Inc(MGRX)'s stock price today?
The current price of MGRX is $0.53. The 52 week high of MGRX is $2.75 and 52 week low is $0.16.
When is next earnings date of Mangoceuticals Inc(MGRX)?
The next earnings date of Mangoceuticals Inc(MGRX) is 2026-08-14 Est..
Does Mangoceuticals Inc(MGRX) pay dividends? If so, how much?
Mangoceuticals Inc(MGRX) does not pay dividend.
Guru Commentaries on NAS:MGRX
No articles.
Press Release
Articles on Mangoceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers